Danavorexton (developmental code name TAK-925) is a selective orexin 2 receptor agonist.

[1][2] The compound was found to dose-dependently produce wakefulness to a similar degree as modafinil in a phase 1 clinical trial.

[1][3] As of March 2021, danavorexton is under development for the treatment of narcolepsy, idiopathic hypersomnia, and sleep apnea.

[2][1][4] It is related to another orexin receptor agonist, firazorexton (TAK-994), the development of which was discontinued for safety reasons in October 2021.

This drug article relating to the nervous system is a stub.